Enterohepatic Transcription Factor CREB3L3 Protects Atherosclerosis via SREBP Competitive Inhibition.

Animals Atherosclerosis / etiology Cyclic AMP Response Element-Binding Protein / physiology Female Gene Expression Regulation Hyperlipidemias / etiology Lipid Metabolism Lipogenesis Male Mice Mice, Inbred C57BL Mice, Knockout Receptors, LDL / physiology Sterol Regulatory Element Binding Proteins / genetics
CREB3L3 Enterohepatic Circulation Hyperlipidemia SREBP

Journal

Cellular and molecular gastroenterology and hepatology
ISSN: 2352-345X
Titre abrégé: Cell Mol Gastroenterol Hepatol
Pays: United States
ID NLM: 101648302

Informations de publication

Date de publication:
2021
Historique:
received: 17 06 2020
revised: 05 11 2020
accepted: 06 11 2020
pubmed: 28 11 2020
medline: 8 3 2022
entrez: 27 11 2020
Statut: ppublish

Résumé

cAMP responsive element-binding protein 3 like 3 (CREB3L3) is a membrane-bound transcription factor involved in the maintenance of lipid metabolism in the liver and small intestine. CREB3L3 controls hepatic triglyceride and glucose metabolism by activating plasma fibroblast growth factor 21 (FGF21) and lipoprotein lipase. In this study, we intended to clarify its effect on atherosclerosis. CREB3L3-deficifient, liver-specific CREB3L3 knockout, intestine-specific CREB3L3 knockout, both liver- and intestine-specific CREB3L3 knockout, and liver CREB3L3 transgenic mice were crossed with LDLR CREB3L3 ablation in LDLR CREB3L3 has multi-potent protective effects against atherosclerosis owing to new mechanistic interaction between CREB3L3 and SREBPs under atherogenic conditions.

Sections du résumé

BACKGROUND & AIMS
cAMP responsive element-binding protein 3 like 3 (CREB3L3) is a membrane-bound transcription factor involved in the maintenance of lipid metabolism in the liver and small intestine. CREB3L3 controls hepatic triglyceride and glucose metabolism by activating plasma fibroblast growth factor 21 (FGF21) and lipoprotein lipase. In this study, we intended to clarify its effect on atherosclerosis.
METHODS
CREB3L3-deficifient, liver-specific CREB3L3 knockout, intestine-specific CREB3L3 knockout, both liver- and intestine-specific CREB3L3 knockout, and liver CREB3L3 transgenic mice were crossed with LDLR
RESULTS
CREB3L3 ablation in LDLR
CONCLUSIONS
CREB3L3 has multi-potent protective effects against atherosclerosis owing to new mechanistic interaction between CREB3L3 and SREBPs under atherogenic conditions.

Identifiants

DOI: 10.1016/j.jcmgh.2020.11.004 PMID: 33246135 PMC: PMC7900604
pubmed: 33246135
pii: S2352-345X(20)30183-1
doi: 10.1016/j.jcmgh.2020.11.004
pmc: PMC7900604
pii:
doi:

Substances chimiques

Creb3l3 protein, mouse 0
Cyclic AMP Response Element-Binding Protein 0
Receptors, LDL 0
Sterol Regulatory Element Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

949-971

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Yoshimi Nakagawa (Y)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki; International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Ibaraki; Division of Complex Bioscience Research, Department of Research and Development, Institute of Natural Medicine, University of Toyama, Toyama. Electronic address: ynaka@inm.u-toyama.ac.jp.

Yunong Wang (Y)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Song-Iee Han (SI)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki; International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Ibaraki.

Kanako Okuda (K)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Asayo Oishi (A)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Yuka Yagishita (Y)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Kae Kumagai (K)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Hiroshi Ohno (H)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Yoshinori Osaki (Y)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Yuhei Mizunoe (Y)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Masaya Araki (M)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Yuki Murayama (Y)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Hitoshi Iwasaki (H)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Morichika Konishi (M)

Department of Microbial Chemistry, Kobe Pharmaceutical University, Hyogo.

Nobuyuki Itoh (N)

Department of Genetic Biochemistry, Graduate School of Pharmaceutical Science, Kyoto University, Kyoto.

Takashi Matsuzaka (T)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Hirohito Sone (H)

Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata.

Nobuhiro Yamada (N)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki.

Hitoshi Shimano (H)

Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Ibaraki; International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Ibaraki; Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Ibaraki; Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), Tokyo, Japan. Electronic address: hshimano@md.tsukuba.ac.jp.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Artériopathies oblitérantes › Artériosclérose › Athérosclérose › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Protéine de liaison à l'élément de réponse à l'AMP cyclique › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles du métabolisme lipidique › Dyslipidémies › Hyperlipidémies › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Métabolisme › Métabolisme lipidique › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Métabolisme › Métabolisme lipidique › Lipogenèse › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux lipoprotéines › Récepteurs aux lipoprotéines LDL › Enterohepatic Transcription Factor CREB3L3...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines › Protéines de liaison à l'élément de régulation des stérols › Enterohepatic Transcription Factor CREB3L3...